Former Treasury Secretary Larry Summers said Monday that he was stepping back from all public commitments amid fallout from the release of emails between him and sex offender Jeffrey Epstein."I am deeply ashamed of my actions and recognize the pain they have caused. I take full responsibility for my misguided decision to continue communicating with Mr. Epstein," Summers said in a statement obtained by CNBC."While continuing to fulfill my teaching obligations, I will be stepping back from public commitments ...

Group 1 - The article does not provide any specific information or insights regarding a company or industry [1]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2025 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number 001-33957 HARVARD BIOSCIENCE, INC. (Exact Name of Registrant as Specified in Its Charter) (State or other jurisdiction of Incorporation or organ ...

Financial Data and Key Metrics Changes - Revenue for Q3 2025 was $20.6 million, at the high end of guidance and slightly up from Q2 2025, but down from $22 million in Q3 2024 [4][11] - Gross margin improved to 58.4%, up from 58.1% in Q3 2024 and exceeded guidance of 56-58% [4][11] - Adjusted EBITDA increased to $2 million from $1.3 million in Q3 2024, driven by reduced operating expenses [11][15] - Operating cash flow was positive at $1.1 million for Q3 2025, contributing to a year-to-date cash flow of $6.8 million compared to negative $0.3 million in the same period last year [16][17] Business Line Data and Key Metrics Changes - Preclinical sales increased sequentially and year-over-year due to growth in telemetry and respiratory product lines [12][13] - The Soho telemetry rollout expanded into additional key accounts, with increased recurring consumable demand [5] - The Biochrome amino acid analyzer for bioproduction performed well, with expectations to exceed last year's consumable revenue [5] Market Data and Key Metrics Changes - Revenue in the Americas increased sequentially by 3.6% but was down 4.4% year-over-year [12] - European revenue increased 0.3% sequentially, reflecting stronger preclinical academic shipments, but was flat year-over-year [13] - In China, revenue was down 6.3% sequentially and 19.6% year-over-year, although there is optimism regarding tariff disruptions [9][13] Company Strategy and Development Direction - The company outlined three priorities for 2025: maintain financial discipline, accelerate product adoption, and strengthen capital structure through debt refinancing [4] - The launch of the Incubate MultiWell system aims to enhance the electrophysiology portfolio and expand into high-throughput applications [6][7] - The company is actively discussing options for refinancing its credit agreement, with expectations to complete this in Q4 2025 [8][17] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about increased demand and backlog heading into Q4 2025, with expectations for continued momentum [9][18] - The ongoing government shutdown may impact NIH funding distribution, which is being monitored closely [8][9] - The company is fundamentally stronger than at the beginning of the year, with a leaner structure and better alignment with long-term growth opportunities [9] Other Important Information - The company expanded its distribution agreement with Fisher Scientific, enhancing access to its products across North America [7] - The adoption of the MeshMEA organoid platform is gaining momentum, supported by regulatory initiatives [8] Q&A Session Summary Question: What drove the uptick in preclinical systems during the quarter? - The uptick was driven by broad demand for telemetry products across various regions and customer groups [20] Question: Is the backlog similar to the existing product mix? - The backlog showed a uniform increase across geographies and products, not driven by any specific product [21][22] Question: What improvements are seen in the academic and government market? - Improvement is reflected in Q3 results and strong backlog, but the potential impact of NIH funding and government shutdown is considered in guidance [23] Question: How does the guidance account for NIH funding and government shutdown? - The lower range of guidance considers the potential for a prolonged government shutdown affecting funding [27] Question: Will NIH funds flow through sales in the first quarter of next year if not released in Q4? - Funds are not lost but will be delayed, potentially impacting orders in Q1 or Q2 of 2026 [28] Question: What is the status of the ERP project? - The ERP project was completed in Q4, contributing to reduced expenses and operational efficiencies [30]

NASDAQ: HBIO 3Q25 Earnings Presentation John Duke, President & CEO Mark Frost, Interim CFO & Treasurer November 6, 2025 Forward-Looking Statements and Non-GAAP Financial Information Forward-Looking Statements This document contains forward-looking statements within the meaning of the federal securities laws, including the Private Securities Litigation Reform Act of 1995. Forward- looking statements may be identified by the use of words such as "may," "will," "expect," "plan," "anticipate," "estimate," "inte ...

Exhibit 99.1 Harvard Bioscience Announces Third Quarter 2025 Financial Results HOLLISTON, Mass., November 6, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the "Company") today announced financial results for the third quarter and nine months ended September 30, 2025. "Our third-quarter performance highlights our growth opportunity while we advance efforts to fortify our capital structure. We saw another uptick in our performance on a sequential basis as our focus on executing, accelerati ...

Core Insights - Harvard Bioscience, Inc. reported third-quarter 2025 revenues of $20.6 million, a decrease from $22.0 million in the same quarter of 2024, but with a gross margin improvement to 58.4% from 58.1% year-over-year [3][4] - The company experienced a net loss of $1.2 million in Q3 2025, significantly reduced from a net loss of $4.8 million in Q3 2024, which included a non-cash charge related to a pension settlement [4] - Adjusted EBITDA for Q3 2025 was $2.0 million, up from $1.3 million in Q3 2024, indicating improved operational performance [4][10] - The company anticipates fourth-quarter 2025 revenues between $22.5 million and $24.5 million, reflecting increased demand and a growing backlog [8][10] Financial Performance - For the nine months ended September 30, 2025, revenues totaled $62.8 million, down from $69.6 million in the same period of 2024, with a gross margin of 56.9%, down from 58.6% [6] - The net loss for the nine months was $53.8 million, compared to a net loss of $12.4 million in the prior year, primarily due to a goodwill impairment of $48.0 million in Q1 2025 [7] - Cash provided by operations for the nine months was $6.8 million, a significant improvement from a cash outflow of $0.3 million in the same period of 2024 [7] Operational Updates - The company is actively negotiating with lenders regarding its credit agreement, aiming for refinancing or repayment in Q4 2025 [5] - Customer engagement has led to the highest backlog level in nearly two years and four consecutive months of order growth, indicating a positive trend in demand [2][10] Guidance - The company expects Q4 2025 revenues to be in the range of $22.5 million to $24.5 million, with gross margins projected between 58% and 60% [8][10]

Core Insights - Harvard Bioscience, Inc. will announce its financial results for Q3 2025 on November 6, 2025, before market opening [1] - A conference call to discuss the results will take place at 8:00 a.m. Eastern Time on the same day [1] - Participants can register to join the call and ask questions, receiving dial-in numbers and a unique PIN upon registration [1] Financial Information - Financial information, including the earnings release and a related slide presentation, will be available on the Investor Relations section of Harvard Bioscience's website [2] Company Overview - Harvard Bioscience is a leading developer, manufacturer, and seller of technologies and products for life science applications, including research and pharmaceutical development [3] - The company serves a diverse customer base, including academic institutions, government laboratories, and major pharmaceutical and biotechnology firms [3] - Operations are conducted in the United States, Europe, and China, utilizing both direct and distribution channels for global sales [3]

Core Insights - Harvard Bioscience has expanded its distribution agreement with Fisher Scientific to include the U.S. market, enhancing customer reach and access to its products [1][2][3] - The collaboration aims to improve customer experience through streamlined ordering, faster delivery, and localized support [3] - This strategic move aligns with Harvard Bioscience's mission to provide high-performance instruments that facilitate scientific discovery [2] Company Overview - Harvard Bioscience is a leading developer and manufacturer of technologies and products for life science applications, serving a diverse customer base including academic institutions and pharmaceutical companies [4] - The company operates in the U.S., Europe, and China, utilizing both direct and distribution channels for global sales [4]

Core Insights - Harvard Bioscience, Inc. has appointed Stephen DeNelsky to its Board of Directors, effective September 5, 2025, enhancing its governance and strategic direction [1][2]. Company Overview - Harvard Bioscience is a leading developer, manufacturer, and seller of technologies and services that advance life science applications, including research, drug discovery, and preclinical testing [5]. Board Member Profile - Stephen DeNelsky brings 30 years of experience in healthcare equity research and analysis, currently serving as Managing Director at Oaktree Capital Management, with prior roles at Marathon Asset Management and Life Sciences Alternative Funding [3]. - DeNelsky has extensive board experience, currently serving on the board of Visioncare Inc and previously on the boards of Integrated Diagnostics and AMICAS, Inc [3]. Leadership Comments - John Duke, President & CEO, emphasized the importance of DeNelsky's financial strategy expertise for the company's future [2]. - Katherine Eade, Lead Independent Director, noted the immediate benefits of DeNelsky's life sciences lending expertise [4].